Insurance coverage has already started from jan 2013 , do your DD basher !!
Insurance pays for my Vascepa, and it has been shown to benefit your heart.
Jefferson why don't you get some info out of carnegie meet up with him and bash his head into the ground
Heh bloodsucker: What do ya call the lastest two weeks of action in AMRN stock---a run-down?
Akanz: An excellent post given a thumbs up! You have sussinctly summerized what I think is the reasoning behind the advisory meeting.
The fact that the patient population to be served is very large is an underlying reason, but not the critical reason. The FDA surely does not want to have healthcare to pay for Nissens unproven clinical benefit in advance. But: Its the two perspective you state later that drive this meeting. Ballantynes perspective versus Nissen perspective.
The meeting is going to pay lip service to the safety and efficacy results of ANCHOR. The real heavy discussion will be the Ballanytne perspective versus Nissen and it will get heavy. Whose perspective will win the day? This is why the total roster mak-up is critical and should be examined with a fine toothed comb before plowing your final money into this meeting!
You state that your money is with Ballantyne perspective.
AF obviosly is marketing that Nissen will win!
Me---I hope ballantyne wins, but I am not cocky enough to be so sure? Nissen route is the safe route "politically" and that is what scares me given the FDA healthy risk/political history therefore I will play it down the middle, take some profit into the meeting given a decent chance, take some shares into the meeting itself and hope Ballantyne wins. I admit this gambit can winsave me money or lose me money. In the end i don;t know who is going to win here!
Because in my mind if Nissen wins, then AMRN is stuck until 2016 unless they can negotiate an interim analysis to be added into Reduce-it, to reduce the time to a re-submission. A timepoint to examine the data pre 2016 which should have been in the protocol in the first place!
This all supports my cautiousness heading into the meeting---it could work out great, but its not a done deal! Everybody will believe what they will believe!
sadie: they have a stable of rosterplayers in that therapeutic level they draw from----sure the roster is not finalized or published yet. Eventually we will find it within the FDA website as will we find the briefing documents a couple days before the meeting itself!
The roster finalization is likely being finalized as memeber must review the brifing documents long before you will get to see them. The good news is AMRN gets them long before the meeting as well---we are the ones left out until the end!
You're really not too bright, troll.
Insurance already covers Vascepa well in the Marine indication..... quickly moving it to Tier 2 in many cases. It will do the same in the Anchor population when it's approved on time.
Additionally, the JELIS study did show a reduction in CV events. In fact, the FDA is allowing Amarin to use the Jelis data in promoting it's drug.
Next time try posting something even the least bit factual troll.
Sentiment: Strong Buy
Must be another alias of the same troll(s) we've seen before on this message board for over a year. They always use the same phrase "decades old product". Get a new catch phrase and you might be harder to spot.
Yes, from what I understand the briefing documents are usually made public a couple of days beforehand. will be useful to go over them. Do you think the Street will be liveblogging in a fair and unbiased way?
Great point of reference for the relative results that could be expected. AND, my research with friends that I know (4) that are on statins and now have added V to their scripts is also important. The results they are seeing and the DRAMTATIC CHANGE in how they feel is the real benefit. All have less joint pain, inflammation, and they say that their attention span and brain functions seem much improved. Overall, they just feel better. Quality of life AND improved bio markers is a big deal.
Dallas, in addition to what you said: coverage for Anchor will progress faster than for Marine, seeing that there is no approved alternative for the Anchor indication.
Not exactly a nobody.
"The stock whisperer has trained over 1000 traders how to trade all around the world. She teaches her students online how to day trade and swing trade by reading the tape, how to spot refreshing, and to enter only on the highest probability trades.
Professional Equities, Options Technical Swing Trader New york"
Intelligence....The Holy Grail of bashers....
"She" is on stock twits. There is a thread over there that is heavily bullish on AMRN. Bio lucky must be talking about SA guy "stock whisperer" also bullish. Everywhere I look AMRN is expected to go higher as we move further into fall.
I feel like I have lost my mind!
I'm just sick and tired of all this bullsh**.
I've HAD IT!!!!
We have a steady stream of random a**holes on Seeking Alpha writing glowing articles about the magic of Vascepa. We have a steady stream of a**holes on Motly Fool writing Vascepa is dead articles. We have lunatics using tens of Yahoo board names holding phony conversations here on this board talking about Vascepa and how it will cure cancer.
It is just an omega 3. People have been taking omega 3's forever. Vascepa is pure epa. People have been taking pure epa for a decade. There is nothing magic about Vascepa. It does what epa has always done. But there is also nothing tragic about Vascepa. The only issue is whether or not omega 3 (epa) reduces cardiac events. If Vascepa's Reduce-it trial shows significance, then Vascepa will have been shown to have value.
With new and better ways to control cholestorol, who knows if omega 3's (and Vascepa) will have any use. Sure PCSK9 inhibitors are exciting, but maybe epa can be taken with them as well? Maybe not, but we won't know until PCSK9 inhibitors are available for Amarin to begin testing.
There is value to epa products, Vascepa is an epa product. That is it. It isn't a magic blockbuster and it isn't dead in the water.
I am just so sick and tired of all the imbecile a**holes trying to manipulate AMRN stock with their faux excitement or fear. #$%$** You a**holes!
The below quotes are from fools article, just wanted to know what was Vascepa-statin result in reducing cholesterol ?? Is it better than the below ??
"In a pooled analysis of four phase 2 trials, Amgen's AMG145 lowered cholesterol by 40%-59%, versus 0.1%-0.5% in placebo-treated patients after 12 weeks of treatment. Alirocumab reduced LDL, or "bad" cholesterol, by 73% when combined with a statin, compared to a 17% reduction in patients receiving statin and placebo. Phase 2 trials gave AMG145 a dosing advantage, though both drugs are currently in phase 3 trials with even more convenient dosing schedules. "
Sentiment: Strong Buy